IPO Grey Market Premium (GMP): How It Works and Should You Trust It

Every IPO season, one number travels faster than the prospectus itself: the IPO Grey Market Premium, or GMP. It is whispered in trading groups, screenshotted across WhatsApp, and treated by many first-time applicants as a near-guarantee of listing-day profit. With India crossing 21.59 crore demat accounts by December 2025 and over 370 companies raising roughly ₹1.95 lakh crore through IPOs that year, the audience watching GMP has never been larger. But here is the uncomfortable question this guide answers honestly: the grey market premium tells you what a crowd expects — not what will actually happen. Let's unpack how GMP works, where the kostak and subject-to-sauda rates fit in, and what 2025's listing data really says about trusting it.

What Is the IPO Grey Market Premium (GMP)?

The IPO grey market premium is the extra price, over and above the issue price, at which IPO shares or applications change hands unofficially before the stock lists on the exchange. If a share is offered at ₹100 and the grey market quotes a GMP of ₹40, buyers are informally agreeing to pay ₹140 for that share ahead of listing.

The "grey market" is not a place. It is a loose, dealer-run network that settles in cash, keeps no formal records, and operates entirely outside the exchanges, SEBI, and your broker. Nobody clears these trades. There is no recourse if a counterparty walks away. That informality is exactly why GMP can be useful as a sentiment thermometer — and exactly why it can mislead.

So why does the grey market exist at all? Because demand for a hot IPO builds before listing, and some participants want exposure earlier, while others want to lock in a profit without waiting for allotment. GMP is simply the price that this off-market tug-of-war settles at on a given day. It moves daily, sometimes hourly, on rumour, subscription figures, and overall market mood.

Understanding GMP properly is really about understanding how IPOs are priced and demanded in the first place — the same foundation a structured stock-market training program is built to give you, instead of piecing it together from grey-market screenshots.

How GMP Is Quoted: Kostak Rate vs Subject-to-Sauda

Most beginners think GMP is a single number. In the grey market itself, premiums are quoted in three related ways, and the distinction matters if you ever hear these terms thrown around.

The plain GMP (per share)

This is the headline figure most websites publish: the premium per share over the issue price. It is the easiest to quote and the easiest to manipulate, because a handful of small trades can move it.

Kostak rate

The kostak rate is a fixed premium paid to buy your entire IPO application outright — whether or not it receives any allotment. If you sell your application at a kostak rate of ₹700, you pocket that amount regardless of the allotment lottery. The buyer takes on the full allotment risk. Kostak is essentially insurance against not getting allotted: a guaranteed small sum in exchange for surrendering any listing upside.

Subject-to-sauda

Subject-to-sauda (often written "subject2sauda") is a conditional deal: a premium that is paid only if the application actually receives an allotment. No allotment, no payment. Because the buyer only pays when shares are secured, subject-to-sauda rates are usually higher than kostak rates for the same IPO. The table below shows how the two differ in plain terms.

All three quotes are informal, unregulated, and unenforceable. They are useful as a window into sentiment — not as a contract you should rely on.

Does GMP Actually Predict Listing Gains? What 2025 Data Shows

This is where the grey market premium meets reality, and 2025 was a brutal teacher. The headline you rarely hear: even in a record fundraising year, listing-day gains shrank dramatically. The median listing gain for mainboard IPOs fell to just 3.8% in 2025, down from 15.2% in 2024, according to year-end reviews from sources including indmoney and Business Standard.

The distribution matters even more than the median. Of the mainboard IPOs that listed in 2025, roughly 65% opened at a profit, around 23% opened at a loss, and the rest were broadly flat. Put differently, nearly one in four mainboard IPOs listed below their issue price — many of them after carrying healthy grey-market premiums right up to listing day.

Practitioner estimates put GMP's historical "accuracy" somewhere in the 60–80% range depending on the market, but that accuracy has visibly eroded. Analyses of 2025 found that roughly a third of mainboard IPOs listed below the gains their peak GMP had implied — including heavily oversubscribed issues. There were also stark single-name examples: GMP for some marquee listings reportedly collapsed sharply in the days before listing, while another widely tracked name whose GMP suggested a 6–7% pop reportedly opened with barely a 1% premium. GMP captures the crowd's appetite; it does not underwrite the result.

When GMP Is a Clearer Signal — and When It's Just Noise

GMP is not useless. Used carefully, it is a real-time read on crowd appetite. The skill is knowing which readings carry information and which are mostly froth. A few patterns recur across IPO cycles.

Negative or zero GMP is more trustworthy than a high positive GMP. When the grey market refuses to pay any premium at all, it is a genuine warning sign — that absence of demand is hard to fake. A sky-high positive GMP, by contrast, is easiest to inflate with thin trades and loudest in euphoric markets, exactly when it overstates reality.

GMP is also a poorer guide for SME issues than mainboard ones, because the grey market for small companies is thinner and easier to push around. The closer you get to listing day on a large, well-subscribed mainboard IPO, the more a stable GMP reflects real demand rather than wishful thinking.

It also helps to remember what a grey market premium can never tell you: the quality of the underlying business, the fairness of the asking valuation, or how the company actually intends to deploy the money it raises. A premium is a popularity reading taken in a thin, unofficial market — genuinely useful as a quick mood check, but useless as a substitute for doing the homework yourself. The investors who consistently come out ahead in IPOs treat GMP exactly that way: a final glance, never the first or the deciding one.

Mistakes Retail Investors Make With GMP

The grey market premium does the most damage not because the number is wrong, but because of how people use it. Watch for these recurring traps:

• Treating GMP as a promise. A ₹120 GMP is a quote, not a payout. It can halve overnight on a weak subscription day.
• Ignoring fundamentals entirely. GMP says nothing about valuation, debt, promoter quality, or how the company plans to use the money. Read the prospectus, not just the premium.
• Chasing SME GMPs. The flashiest premiums often sit on the thinnest, most manipulable grey markets.
• Applying only for listing gains. When the median listing pop is under 4%, the "apply, sell, repeat" trade is far less rewarding than it was in 2024.
• Confusing GMP with allotment odds. A high GMP does not improve your chance in an oversubscribed lottery; it often worsens it.

None of this means avoid IPOs. It means treat GMP as one input among many. Learning how to analyse an IPO before you apply — the DRHP, valuations and red flags — will serve you far longer than any premium tracker.

How to Use GMP Sensibly: A Pre-Application Checklist

If you still want to factor GMP into your decision — and used well, there is no harm in it — run it through a disciplined process instead of reacting to a screenshot. A sensible sequence looks like this:

1. Read the prospectus first. Form a view on the business and the asking valuation before you ever look at GMP.
2. Check subscription data. Strong, broad-based institutional demand is more durable than a high grey-market quote.
3. Look at GMP last, and look at its trend. A premium that is steady or rising into listing is more informative than one snapshot.
4. Respect a negative GMP. If the grey market won't pay up, take that warning seriously.
5. Decide your exit before listing. Listing-gain seller or long-term holder — choose deliberately, and check your IPO allotment status promptly so you can act.

The investors who do well with IPOs are not the ones with the best GMP feed. They are the ones who understand pricing, demand and risk well enough that the grey market simply confirms — or contradicts — a view they already hold.

Frequently Asked Questions

What is GMP in an IPO in simple words?

GMP, or grey market premium, is the extra amount over the issue price that buyers are informally willing to pay for IPO shares before they list on the exchange. A ₹50 GMP on a ₹100 share means the grey market is valuing it near ₹150 pre-listing. It reflects expected demand, not a guaranteed listing price.

Is it legal to trade in the IPO grey market?

The grey market is unofficial and unregulated — it operates outside SEBI, the exchanges and your broker, and trades settle in cash on trust. It is not formally illegal to discuss or track GMP, but actual grey-market trades carry no legal protection or recourse. For most retail investors, GMP is best used only as a sentiment indicator.

Does a high GMP guarantee listing gains?

No. In 2025, the median mainboard listing gain fell to about 3.8%, and nearly one in four mainboard IPOs listed at a loss — many despite carrying positive GMPs. A high GMP signals optimism, but it can collapse before listing and frequently overstates the actual opening move.

What is the difference between kostak and subject-to-sauda?

Kostak is a fixed premium you receive for selling your IPO application whether or not it gets allotted. Subject-to-sauda is paid only if your application receives an allotment. Kostak is the safer, smaller, guaranteed sum; subject-to-sauda is higher but conditional on allotment.

Where can I check IPO GMP, and should I rely on it?

Several finance websites publish daily GMP estimates, but figures vary between sources because the market is informal. Treat any single number with caution: read the prospectus, check subscription data, and use GMP only as a final, supporting input rather than the basis of your decision.

Disclaimer: This article is for educational purposes only and does not constitute investment advice. Markets carry risk — please do your own research or consult a qualified financial professional before investing. NIFM provides training and exam preparation; certification exams conducted by regulatory or professional bodies are administered by those bodies independently.